Mesoblast (MESO) Sees Optimism From Analysts
Mesoblast Limited (NASDAQ:MESO) is a biotechnology company developing treatments for inflammatory diseases, heart failure, and other ailments.
Mesoblast Ltd (MESO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 229,800 | $3,702,078 | +63% | 0% | |
| 2. | 66,100 | $1,064,871 | +5% | 0% | |
| 3. | Squarepoint Ops LLC Maxime Fortin (Cio) | 31,656 | $509,978 | +117% | 0% |
| 4. | AQR Capital Management Cliff Asness | 13,973 | $225,105 | +1% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 87,575 | $1,579,853 | 1.09% | |
| 2. | 46,500 | $838,860 | 0.2% | |
| 3. | 46,121 | $832,023 | 0.28% | |
| 4. | 16,000 | $288,640 | 0.1% | |
| 5. | 14,017 | $252,866 | 0% |
News See All
7 Best ASX Stocks to Buy Right Now
While the Federal Reserve cut interest rates in the US a couple of days back, in Australia, the trend appears to be moving in the opposite direction.
Mesoblast's Ryoncil Gains Permanent CMS J-Code for Billing and Reimbursement
Mesoblast Limited (NASDAQ:MESO) is one of the best hot stocks to invest in.
12 Best Hot Stocks to Invest In
On September 24, Ryan Detrick, Carson Group chief market strategist, joined CNBC's 'Power Lunch' to discuss why he still expects a strong end-of-year rally.
Mesoblast Limited (MESO)’s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs
Mesoblast Limited (NASDAQ:MESO) is a global leader in developing allogeneic, off-the-shelf cellular medicines for inflammatory diseases.
12 Healthcare Stocks with Insider Buying in 2025
In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, with divergent trends in technology adoption, investment, and fundraising.
Mesoblast Limited (NASDAQ:MESO) Q4 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Mesoblast Financial Results for the Full Year Ended June 30, 2025.
Canaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy Rating
Mesoblast Limited (NASDAQ:MESO) is among the 12 Best Australian Stocks to Buy Right Now.
12 Best Australian Stocks to Buy Right Now
Australia’s S&P/ASX 200 index advanced 0.53% on Thursday to close at 8,873.80, with investors buoyed by gains in the banking sector, amid robust earnings and renewed hopes for further interest rate ...
Mesoblast Limited (MESO) Launches First Cell Therapy for Children
Mesoblast Limited (NASDAQ:MESO) is among the best mid-cap stocks to buy according to billionaires.